Link to study

World Journal of Gastroenterology, 2017 By Prince M, Lester L, Chiniwala R and Berger B1

Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients1


Objective

"To determine the uptake of noninvasive multitarget stool DNA (mt-sDNA) in a cohort of colorectal cancer (CRC) screening non-compliant average-risk Medicare patients."


Study design

  • Retrospective, cross sectional, primary care office-based study of 393 patients from USMD Health System, across 77 providers
  • Identified mt-sDNA use in unscreened patients who were either >10 years since last colonoscopy and/or >1 year since last fecal occult blood test
  • Key outcome measures included mt-sDNA compliance and diagnostic colonoscopy compliance on positive cases

Study limitations

  • Relatively small study size from a single health center; findings may not be generalizable to non-Medicare-age patients nor to geographic area of study (Dallas, TX)

Study findings

88.3%
347 of the 393 previously noncompliant patients completed the Cologuard test
96.1%
Of the 51 patients with positive mt-sDNA results, 49 underwent a follow-up diagnostic colonoscopy

REFERENCES 1. Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World Journal of Gastroenterology. 2017;23(3):464-471. doi:10.3748/wjg.v23.i3.464.